Newsletters

[Thomas Jefferson University (Audacy)] The PA Breast Cancer Coalition has awarded two Thomas Jefferson University researchers with $100,000 grants to advance groundbreaking work in triple-negative breast cancer and immunotherapy.

[Cancer Research] Investigators showed that EZH2 inhibitors shift the epigenetic state of human epidermal growth factor receptor 2–positive (HER2+) tumors, dramatically enhancing baseline responses to HER2 kinase inhibitors and resensitizing drug-resistant tumors in vitro and in vivo.

[Cancer Research] Researchers showed that β-hydroxybutyrate levels were markedly decreased in tumor tissues and serum from patients with breast cancer, particularly in metastatic patients.

[AstraZeneca] AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for Enhertu has been accepted and granted Priority Review in the US for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment.

[Cell Death Discovery] The authors compile recent advancements in the understanding of pyroptosis as a therapeutic target in breast cancer and discuss the molecular pathways responsible for regulating pyroptosis, the expression and roles of gasdermin proteins in breast cancer, and the modulation of pyroptosis to improve anticancer efficacy and address drug resistance.

[Communications Biology] Researchers used a three-dimensional microglia-embedded human neural organoid model to investigate HIV-1–induced immunometabolic changes in the brain.

[ACS Biomaterials Science & Engineering] The authors review recent progress in engineering retinal organoids and eye-on-a-chip models for modeling degenerative eye diseases, with a focus on engineering innovations.

[Cellular Oncology] Researchers established primary liver cancer organoids from three major subtypes—hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma—to enable precise diagnostics and personalized therapies through comprehensive genomic profiling.

[Advanced Healthcare Materials] Scientists introduced OrganoidMap, an open-access, interactive web platform for exploring, filtering, and comparing cerebral organoid models across disease areas, cell sources, and methodological features.

[International Journal of Cancer] Investigators examined how non-genetic parameters such as organoid size, seeding density, and morphology affect proliferation, drug sensitivity, and Wnt responses in a murine colorectal cancer organoid model carrying oncogenic Apc, Braf, and Trp53 mutations.

[FDA (Fierce Biotech)] The FDA’s Center for Drug Evaluation and Research (CDER) released new draft guidance March 18 specifying that drug approval applicants are welcome to submit data from new approach methodologies (NAMs) like organoids, organs-on-chips and computational models, even if the method hasn’t previously been OK'd by the agency to replace animals.

[Johns Hopkins Bloomberg School of Public Health] A team of Johns Hopkins researchers has been awarded a five-year $15 million grant from the NIH to develop a platform to test potential new treatments for neurological diseases such as Alzheimer’s, and to screen for harmful chemicals.